Addington Investment Group
Rivium Quadrant 2, Capelle aan den IJssel, Zuid-Holland, 2909 LD, The Netherlands
Overview
Addington, founded by top-level executive and serial entrepreneur Ad Nederlof, invests in startups and scaleups that require funding and hands-on experience to accommodate growth. Addington aims at acquiring minority equity positions in startups and scaleups that require funding and targeted support in order to take the next step in their development. Addington’s expertise is highly varied, but best serves companies that offer scalable solutions on a recurring revenue model. Eligible companies ideally have a turnover of € 2 million and the potential to achieve continuous annual growth of 25 percent or higher. Besides funding, Addington provides guidance and advice based on many years of entrepreneurship and experience in international business. Addington holds standards and values that correspond with a genuine family business. To take full advantage of our expertise, a cultural match is a prerequisite. Internationally acclaimed business executive and entrepreneur Ad Nederlof is the classic example of “newspaper boy to captain of industry”. With little or no formal schooling to boast, he now holds a career of well over 50 years in the IT-industry – and the end is by no means in sight. Started off as a sales representative he worked his way up to executive positions until he could grow no further. Curious to put his vision of delivering excellent customer service to the test – and his own money where his mouth was – in 2005, at the age of 57, he started VANAD (‘owned by Ad’). Spurred by his enthusiasm, VANAD has grown from 20 to 2,000 employees since then. Throughout the years Ad added several rapidly growing companies to the portfolio. One of them, Enovation, he sold in 2018 for over € 100 million. Money he is now putting to work through Addington. With his vision, drive and insights as an invaluable bonus for entrepreneurs who – just like Ad – like to push further.
- Total investments
- 1
- Lead investments
- 1
- Investments · 12mo
- 1
- Active investors
- 3
Sector focus
- Health Care
- Information Technology
- Internet
- Professional Services
- Software
Investment portfolio
- MimeCure
Led · Equity · May 2026
MimeCure is developing MC002, an active fragment of the body's mimecan protein formulated for inhalation to deliver the agent directly to the lungs. The therapy is designed to combine reduction of scar formation with activation of the lung's natural repair capacity, and development is initially focused on idiopathic pulmonary fibrosis (IPF) with exploration of applicability to COPD and other fibrotic conditions. The company frames MC002 as a potentially regenerative approach that seeks to repair damaged tissue rather than only slow disease progression. MimeCure plans to complete preclinical studies with current funding and begin preparing for first human trials expected at the end of 2027. The company was founded by Luke van der Koog and Erik Frijlink as a University of Groningen spin-off and collaborates closely with the University Medical Center Groningen.